Takayuki Sumiyoshi

9PUBLICATIONS
54CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 25, 2026
Clinical value of prostate-specific antigen halving time as a predictor of response to first-line systemic treatment for synchronous metastatic castration-sensitive prostate cancer.

|May 14, 2026
Dual inhibition of PARP and ATR induces synthetic lethal vulnerability in prostate cancer with CDK12 deficiency.

|Jan 16, 2026
Association between preoperative interruption of antiplatelet therapy and postoperative thrombotic risk after minimally invasive surgery for abdominopelvic cancer in patients treated with P2Y12 inhibitors.

Masashi Kubota, Satomi Yoshida, Takayuki Goto

|Sep 10, 2025
Development of a novel risk model to predict CRPC progression following IMRT: Implications for tailoring treatment intensity.

Takashi Ogata, Rihito Aizawa, Hiroyasu Abe

|Jan 06, 2025
Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer.

Toru Sakatani, Takayuki Sumiyoshi, Yuki Kita

|Mar 29, 2024
Prostate cancer and liquid biopsies: Clinical applications and challenges.

Fumihiko Urabe, Takayuki Sumiyoshi, Kojiro Tashiro

Pageof 2

Frequent Collaborators

6 joint publications

Takashi Kobayashi

4 joint publications

Takayuki Goto

2 joint publications

Ryoichi Saito

2 joint publications

Shusuke Akamatsu